medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2019-1-18(393)-13-23medalphabet-1266Research ArticleСтатьиАнализ применения селективного модулятора костимуляции Т-лимфоцитов абатацепта в лечении ревматоидного артрита: данные международной клинической практикиAnalysis of the use of a selective modulator of cosmulation of T‑lymphocytes abatacept in the treatment of rheumatoid arthritis: data from international clinical practiceБорисоваМ. А.BorisovaM. A.

м. н. с. лаборатории изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

г. Москва

Moscow

ЛукинаГ. В.LukinaG. V.

д. м. н., проф., зав. научно-исследовательским отделом ревматологии

г. Москва

Moscow

ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»; ГБУЗ «Московский клинический научно-практический центр имени А. С. Логинова» Департамента здравоохранения г. МосквыРоссияV.A. Nasonova Research Institute of Rheumatology; A. S. Loginov Moscow Clinical Scientific CenterRussian Federation201926112019118Ревматология в общей врачебной практике1323Copyright © Борисова М.А., Лукина Г.В., 20192019Борисова М.А., Лукина Г.В.Borisova M.A., Lukina G.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1266

В данной статье приведены результаты международных исследований, посвященных изучению эффективности, безопасности АБЦ и выявлению возможных предикторов хорошего ответа на терапию данным препаратом в условиях реальной клинической практики.

This article presents the results of international studies of abatacept efficacy and safety and searching for possible predictors of a good response to the therapy with this drug in real clinical practice.

абатацептгенно‑инженерные биологические препаратыревматоидный артритabataceptbiologicsrheumatoid arthritisReferencesSchiff M. M., Bessette L. Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. Clinical Rheumatology, 29, 583–591. DOI: 10.1007/s10067–009–1363–0.Schiff M. M., Bessette L. Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. Clinical Rheumatology, 29, 583–591. DOI: 10.1007/s10067–009–1363–0.Александрова ЕЛ, Новиков АА, Насонов ЕЛ. Роль Т-клеток в патогенезе ревматоидного артрита. Науч-практич ревматол 2010; 4; 2: 3–9Aleksandrova EL, Novikiov AA, Nasonov EL. Rol T-kletok v patogeneze revmatoidnogo artrita. [Role of T-cells in pathogenesis of rheumatoid arthritis] Rheum science and practice 2010; 4; 2: 3–9.Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol. 2007 Sep-Oct; 25 (5 Suppl 46): S 4–11.Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol. 2007 Sep-Oct; 25 (5 Suppl 46): S 4–11.Korhonen R, Moilanen E. Abatacept, a novel CD 80 / 86-CD 28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009 Apr; 104 (4): 276–84. DOI: 10.1111/j.1742–7843.2009.00375.x.Korhonen R, Moilanen E. Abatacept, a novel CD 80 / 86-CD 28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009 Apr; 104 (4): 276–84. DOI: 10.1111/j.1742–7843.2009.00375.x.Kremer JM, Genant HK, Moreland LW et al. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis: A Randomized Trial. Ann Intern Med. 2006; 144: 865–876. DOI: 10.7326/0003–4819–144–12–200606200–00003.Kremer JM, Genant HK, Moreland LW et al. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis: A Randomized Trial. Ann Intern Med. 2006; 144: 865–876. DOI: 10.7326/0003–4819–144–12–200606200–00003.Kremer JM, Genant HK, Moreland LW, et. al. Results of a two-year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008 Apr; 58 (4): 953–963. DOI: 10.1002/art.23397.Kremer JM, Genant HK, Moreland LW, et. al. Results of a two-year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008 Apr; 58 (4): 953–963. DOI: 10.1002/art.23397.Schiff M, Keiserman M, Codding C, et. al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis. 2011 Nov; 70 (11): 2003–7. DOI: 10.1136/annrheumdis-2011–200316.Schiff M, Keiserman M, Codding C, et. al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis. 2011 Nov; 70 (11): 2003–7. DOI: 10.1136/annrheumdis-2011–200316.Genovese MC, Becker JC, Schiff M, et. al. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition. N Engl J Med 2005; 353: 1114–1123 Sept 15, 2005 DOI: 10.1056/NEJMoa050524.Genovese MC, Becker JC, Schiff M, et. al. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition. N Engl J Med 2005; 353: 1114–1123 Sept 15, 2005 DOI: 10.1056/NEJMoa050524.Weinblatt M, Combe B, Covucci A, et. al. Safety of the Selective Costimulation Modulator Abatacept in Rheumatoid Arthritis Patients Receiving Background Biologic and Nonbiologic Disease-Modifying Antirheumatic Drugs. A OneYear Randomized, Placebo-Controlled Study. Arthritis Rheum. 2006 Sep; 54 (9): 2807–2816. DOI: 10.1002/art.22070.Weinblatt M, Combe B, Covucci A, et. al. Safety of the Selective Costimulation Modulator Abatacept in Rheumatoid Arthritis Patients Receiving Background Biologic and Nonbiologic Disease-Modifying Antirheumatic Drugs. A OneYear Randomized, Placebo-Controlled Study. Arthritis Rheum. 2006 Sep; 54 (9): 2807–2816. DOI: 10.1002/art.22070.Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009 Nov; 68 (11): 1708–14. DOI: 10.1136/ard.2008.099218.Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009 Nov; 68 (11): 1708–14. DOI: 10.1136/ard.2008.099218.Wells AF, Westhovens R, Reed DM, et. al. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol. 2011 Nov; 38 (11): 2362–8. DOI: 10.3899/jrheum.110054.Wells AF, Westhovens R, Reed DM, et. al. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol. 2011 Nov; 38 (11): 2362–8. DOI: 10.3899/jrheum.110054.Emery P, Durez P, Dougados M, et. al. Impact of T-cell costimulation modulation in patients with undifferentiated infl ammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010 Mar; 69 (3): 510–6. DOI: 10.1136/ard.2009.119016.Emery P, Durez P, Dougados M, et. al. Impact of T-cell costimulation modulation in patients with undifferentiated infl ammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010 Mar; 69 (3): 510–6. DOI: 10.1136/ard.2009.119016.Nüßlein HG, Alten R, Galeazzi M et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord. 2014 Jan 11; 15: 14. DOI: 10.1186/1471–2474–15–14.Nüßlein HG, Alten R, Galeazzi M et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord. 2014 Jan 11; 15: 14. DOI: 10.1186/1471–2474–15–14.Alten R, Mariette X, Lorenz H, et al Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study RMD Open 2017; 3: e000538. DOI: 10.1136/rmdopen-2017–000538.Alten R, Mariette X, Lorenz H, et al Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study RMD Open 2017; 3: e000538. DOI: 10.1136/rmdopen-2017–000538.Nüßlein HG, Alten R, Galeazzi M, et al. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskeletal Disorders. 2015; 16: 176. DOI: 10.1186/s12891–015–0636–9.Nüßlein HG, Alten R, Galeazzi M, et al. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskeletal Disorders. 2015; 16: 176. DOI: 10.1186/s12891–015–0636–9.Alten R, Nüßlein H, Galeazzi M, et al. Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open. 2016; 2 (1): e000228. DOI: 10.1136/rmdopen-2015–000228.Alten R, Nüßlein H, Galeazzi M, et al. Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open. 2016; 2 (1): e000228. DOI: 10.1136/rmdopen-2015–000228.Gottenberg JE, Ravaud P, Cantagrel A, et al Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry Annals of the Rheumatic Diseases 2012; 71: 1815–1819.Gottenberg JE, Ravaud P, Cantagrel A, et al Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry Annals of the Rheumatic Diseases 2012; 71: 1815–1819.Truchetet M-E, Poursac N, Barnetche T, et al. Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry. Arthritis Research & Therapy. 2016; 18: 72. DOI: 10.1186/s13075–016–0956–7.Truchetet M-E, Poursac N, Barnetche T, et al. Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry. Arthritis Research & Therapy. 2016; 18: 72. DOI: 10.1186/s13075–016–0956–7.Leffers HC, Østergaard M, Glintborg B, et al Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry Annals of the Rheumatic Diseases 2011; 70: 1216–1222.Leffers HC, Østergaard M, Glintborg B, et al Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry Annals of the Rheumatic Diseases 2011; 70: 1216–1222.Leffers HC, Østergaard M, Glintborg B et al. Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with Rheumatoid Arthritis Treated In Routine Care. Results FromThe Nationwide Danish Danbio Registry. ABSTRACT NUMBER: 1442; 2013 ACR / ARHP Annual Meeting; acrabstracts.org/abstract/three-year-drug-survival-and-effectiveness-of-abatacept-and-tocilizumab-in-patients-with-rheumatoid-arthritis-treated-inroutine-care-results-from-the-nationwide-danish-danbio-registry.Leffers HC, Østergaard M, Glintborg B et al. Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with Rheumatoid Arthritis Treated In Routine Care. Results FromThe Nationwide Danish Danbio Registry. ABSTRACT NUMBER: 1442; 2013 ACR / ARHP Annual Meeting; acrabstracts.org/abstract/three-year-drug-survival-and-effectiveness-of-abatacept-and-tocilizumab-in-patients-with-rheumatoid-arthritis-treated-inroutine-care-results-from-the-nationwide-danish-danbio-registry.Leffers HC, Østergaard M, Glintborg B et al. Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry. ABSTRACT NUMBER: 1271; 2012 ACR / ARHP Annual Meeting; acrabstracts.org/abstract/two-year-drug-survival-and-treatment-effect-of-abatacept-and-tocilizumab-in-the-treatment-of-rheumatoid-arthritis-in-routine-care-results-from-the-nationwide-danish-danbio-registry.Leffers HC, Østergaard M, Glintborg B et al. Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry. ABSTRACT NUMBER: 1271; 2012 ACR / ARHP Annual Meeting; acrabstracts.org/abstract/two-year-drug-survival-and-treatment-effect-of-abatacept-and-tocilizumab-in-the-treatment-of-rheumatoid-arthritis-in-routine-care-results-from-the-nationwide-danish-danbio-registry.Kubo S, Saito K, Hirata K et al. (2013) Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study, Modern Rheumatology, 24: 1, 42–51, DOI: 10.3109/14397595.2013.854051.Kubo S, Saito K, Hirata K et al. (2013) Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study, Modern Rheumatology, 24: 1, 42–51, DOI: 10.3109/14397595.2013.854051.Kubo S, Nakano K, Nakayamada S et al. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. Clin Exp Rheumatol. 2016 Sep-Oct; 34 (5): 834–841. Epub 2016 Aug 31.Kubo S, Nakano K, Nakayamada S et al. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. Clin Exp Rheumatol. 2016 Sep-Oct; 34 (5): 834–841. Epub 2016 Aug 31.Horák P, Skácelová M, Hejduk K et al. Clin Rheumatol (2013) 32: 1451. doi.org/10.1007/s10067–013–2303–6. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.Horák P, Skácelová M, Hejduk K et al. Clin Rheumatol (2013) 32: 1451. doi.org/10.1007/s10067–013–2303–6. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.Harrold LR, Reed GW, Kremer JM, et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Annals of the Rheumatic Diseases. 2015; 74 (2): 430–436. DOI: 10.1136/annrheumdis-2013–203936.Harrold LR, Reed GW, Kremer JM, et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Annals of the Rheumatic Diseases. 2015; 74 (2): 430–436. DOI: 10.1136/annrheumdis-2013–203936.Harrold LR, Litman HJ, Connolly SE, et al. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity / remission in clinical practice? Clinical Rheumatology. 2017; 36 (6): 1215–1220. DOI: 10.1007/s10067–017–3588–7.Harrold LR, Litman HJ, Connolly SE, et al. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity / remission in clinical practice? Clinical Rheumatology. 2017; 36 (6): 1215–1220. DOI: 10.1007/s10067–017–3588–7.Schiff M, Poncet C, Le Bars M Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice. Int. J. Clin. Rheumatol. (2010) 5 (5), 581–591.Schiff M, Poncet C, Le Bars M Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice. Int. J. Clin. Rheumatol. (2010) 5 (5), 581–591.Takahashi N, Kojima T, Kaneko A et al. Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity. Clin Rheumatol. 2014 Jan; 33 (1): 39–47. DOI: 10.1007/s10067–013–2392–2. Epub 2013 Sep 22.Takahashi N, Kojima T, Kaneko A et al. Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity. Clin Rheumatol. 2014 Jan; 33 (1): 39–47. DOI: 10.1007/s10067–013–2392–2. Epub 2013 Sep 22.Takahashi N, Kojima T, Kaneko A et al. Longterm Efficacy and Safety of Abatacept in Patients with Rheumatoid Arthritis Treated in Routine Clinical Practice: Effect of Concomitant Methotrexate after 24 Weeks. The Journal of Rheumatology May 2015, 42 (5) 786–793; DOI: 10.3899/jrheum.141288.Takahashi N, Kojima T, Kaneko A et al. Longterm Efficacy and Safety of Abatacept in Patients with Rheumatoid Arthritis Treated in Routine Clinical Practice: Effect of Concomitant Methotrexate after 24 Weeks. The Journal of Rheumatology May 2015, 42 (5) 786–793; DOI: 10.3899/jrheum.141288.Takahashi N, Kojima T, Terabe K et al. Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients. Mod Rheumatol. 2013 Sep; 23 (5): 904–12. DOI: 10.1007/s10165–012–0760–4. Epub 2012 Sep 14.Takahashi N, Kojima T, Terabe K et al. Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients. Mod Rheumatol. 2013 Sep; 23 (5): 904–12. DOI: 10.1007/s10165–012–0760–4. Epub 2012 Sep 14.Mochizuki T, Yano K, Ikari K et al. (2015): The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice, Modern Rheumatology, DOI: 10.3109/14397595.2015.1109578.Mochizuki T, Yano K, Ikari K et al. (2015): The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice, Modern Rheumatology, DOI: 10.3109/14397595.2015.1109578.Tanaka Y, Kubo S, Yamanaka H et al. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia (®) as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol. 2014 Sep; 24 (5): 754–62. DOI: 10.3109/14397595.2013.872862. Epub 2014 Jul 18.Tanaka Y, Kubo S, Yamanaka H et al. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia (®) as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol. 2014 Sep; 24 (5): 754–62. DOI: 10.3109/14397595.2013.872862. Epub 2014 Jul 18.Takahashi N, Fujibayashi T, Kida D et al. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. Rheumatol Int. 2015 Oct; 35 (10): 1707–16. DOI: 10.1007/s00296–015–3283–4. Epub 2015 May 20.Takahashi N, Fujibayashi T, Kida D et al. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. Rheumatol Int. 2015 Oct; 35 (10): 1707–16. DOI: 10.1007/s00296–015–3283–4. Epub 2015 May 20.Pascart T, Philippe P, Drumez E et al. Abatacept Monotherapy Versus Abatacept Plus Methotrexate for Treatment-Refractory Rheumatoid Arthritis. Am J Ther. 2017 Sep 12. DOI: 10.1097/MJT.0000000000000645.Pascart T, Philippe P, Drumez E et al. Abatacept Monotherapy Versus Abatacept Plus Methotrexate for Treatment-Refractory Rheumatoid Arthritis. Am J Ther. 2017 Sep 12. DOI: 10.1097/MJT.0000000000000645.Dudler J, Tuerk R, Handschin T et al. RAISE — rheumatoid arthritis independent Swiss treatment expectations and outcome: results for the abatacept subpopulation. Swiss Med Wkly. 2013 Dec 6; 143: w13849. DOI: 10.4414/smw.2013.13849.Dudler J, Tuerk R, Handschin T et al. RAISE — rheumatoid arthritis independent Swiss treatment expectations and outcome: results for the abatacept subpopulation. Swiss Med Wkly. 2013 Dec 6; 143: w13849. DOI: 10.4414/smw.2013.13849.Yasuda S, Ohmura K, Kanazawa H et al. Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) — A prospective, multicenter, single arm pilot clinical trial. Mod Rheumatol. 2017 Nov; 27 (6): 930–937. DOI: 10.1080/14397595.2017.1286714. Epub 2017 Feb 16.Yasuda S, Ohmura K, Kanazawa H et al. Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) — A prospective, multicenter, single arm pilot clinical trial. Mod Rheumatol. 2017 Nov; 27 (6): 930–937. DOI: 10.1080/14397595.2017.1286714. Epub 2017 Feb 16.Finckh A, Neto D, Hernández MV et al. Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries. ABSTRACT NUMBER: 504. 2014 ACR / ARHP Annual Meeting. acrabstracts.org/abstract/abatacept-after-rituximab-in-rheumatoid-arthritis-a-pan-european-collaboration-of-ra-registries.Finckh A, Neto D, Hernández MV et al. Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries. ABSTRACT NUMBER: 504. 2014 ACR / ARHP Annual Meeting. acrabstracts.org/abstract/abatacept-after-rituximab-in-rheumatoid-arthritis-a-pan-european-collaboration-of-ra-registries.Finckh A, Neto D, Hernández MV et al. Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries. ABSTRACT NUMBER: 504. 2014 ACR / ARHP Annual Meeting. acrabstracts.org/abstract/abatacept-after-rituximab-in-rheumatoid-arthritis-a-pan-european-collaboration-of-ra-registries.Finckh A, Neto D, Hernández MV et al. Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries. ABSTRACT NUMBER: 504. 2014 ACR / ARHP Annual Meeting. acrabstracts.org/abstract/abatacept-after-rituximab-in-rheumatoid-arthritis-a-pan-european-collaboration-of-ra-registries.Das S, Vital EM, Horton S, et al Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy Annals of the Rheumatic Diseases Published Online First: 02 January 2014. DOI: 10.1136/annrheumdis-2013–204417.Das S, Vital EM, Horton S, et al Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy Annals of the Rheumatic Diseases Published Online First: 02 January 2014. DOI: 10.1136/annrheumdis-2013–204417.Piantoni, S., Colombo, E., Tincani, A. et al. Predictive Factors of Discontinuation of Therapy with Abatacept in Patients with Rheumatoid Arthritis Clin Rheumatol (2016) 35: 1065. doi.org/10.1007/s10067–016–3185–1.Piantoni, S., Colombo, E., Tincani, A. et al. Predictive Factors of Discontinuation of Therapy with Abatacept in Patients with Rheumatoid Arthritis Clin Rheumatol (2016) 35: 1065. doi.org/10.1007/s10067–016–3185–1.Лукина ГВ, Сигидин ЯА, Мазуров ВИ и др. Предварительные результаты применения абатацепта в клинической практике. В кн.: Генно-инженерные биологические препараты в лечении ревматоидного артрита. Под. ред. Е. Л. Насонова. Москва: ИМА-ПРЕСС; 2013. С. 386–387.Lukina GV, Sigidin IA, Mazurov VI. Predvaritelnye relutaty primenenia abatacepta v klinicheskoy praktike. In: Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Preliminary results of abatacept treatment in routine practice. In: Genetically engineered biological preparations in treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. P. 386–387.Мазуров ВИ, Долгих СВ и соавт. Опыт применения абатацепта в лечении больных ревматоидным артритом. Научно-практическая ревматология. 2011; 49 (6): 14–16. DOI: 10.14412/1995–4484–2011–513Mazurov VI, Dolgikh SV et al. Opit primeneniya abatacepta v lechenii bolnikh revmatoidnim artritom [Experience with abatacept used in the treatment of patients with rheumatoid arthritis]. Rheumatology Science and Practice. 2011; 49 (6): 14–16. (In Russ.) DOI: 10.14412/1995–4484–2011–513.Лапшина СА, Мясоутова ЛИ, Протопопов МС и соавт. Опыт применения абатацепта в терапии ревматоидного артрита в Республике Татарстан. Научно-практическая ревматология. 2012; 50 (6): 99–102. DOI: dx.doi.org/10.14412/1995–4484–2012–6.Lapshina SA, Myasoutova LI, Protopopov MS et al. Opit primeneniya abatacepta v terapii revmatoidnogo artrita v respublike Tatarstan [Experience with abatacept in the therapy of rheumatoid arthritis in the republic of Tatarstan] Rheumatology Science and Practice. 2012; 50 (6): 99–102. (In Russ.) DOI: 10.14412/1995–4484–2012–1301.Борисова М. А., Лукина Г. В., Сигидин Я. А. и соавт. Анализ эффективности и безопасности применения абатацепта при ревматоидном артрите: результаты 12-месячного наблюдения. Терапевтический архив. 2018; 05: 44–49. doi.org/10.26442/terarkh201890544–49Borisova M. A., Lukina G. V., Sigidin Y. A. et al. Analiz effectivnosti I bezopasnosti primeneniya pri revamatoidnom artrite: rezultati 12-mesyachnogo nabludeniya [Efficacy and tolerability of abatacept treatment: results of 12 months observation] Terapevticheskii arkhiv 2018; 05: 44–49. doi.org/10.26442/terarkh201890544–49.Борисова М. А. Комплексная оценка торможения костимуляции Т-лимфоцитов в современной терапии ревматоидного артрита: автореф. дис. Комплексная оценка торможения костимуляции Т-лимфоцитов в современной терапии ревматоидного артрита канд. мед. наук. ФГБНУ «НИИР» им. В. А. Насоновой, 2019Borisova M. A. Kompleksnaya otsenka tormozheniya T-limfocitov v sovremennoi terapii revmatoidnogo artrita [The comprehensive estimation of selective modulator abatacept in the treatment of rheumatoid arthritis] V. A. Nasonova Research Institute of Rheumatology, 2019.Sekiguchi M., Fujii T, Matsui K et al. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. The Journal of Rheumatology Nov 2016, 43 (11) 1974–1983; DOI: 10.3899/jrheum.160051.Sekiguchi M., Fujii T, Matsui K et al. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. The Journal of Rheumatology Nov 2016, 43 (11) 1974–1983; DOI: 10.3899/jrheum.160051.Pope JE, Rampakakis E, Sampalis J et al. The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study. Semin Arthritis Rheum. 2015 Apr; 44 (5): 499–505. DOI: 10.1016/j.semarthrit.2014.09.009. Epub 2014 Sep 28.Pope JE, Rampakakis E, Sampalis J et al. The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study. Semin Arthritis Rheum. 2015 Apr; 44 (5): 499–505. DOI: 10.1016/j.semarthrit.2014.09.009. Epub 2014 Sep 28.Борисова М. А., Лукина Г. В., Сигидин Я. А., Лучихина Е. Л., Каратеев Д. Е., Аронова Е. С., Глухова С. И. Сравнительная оценка эффективности и безопасности абатацепта у пациентов с разной длительностью ревматоидного артрита. Научно-практическая ревматология. 2016; 54 (6): 667–673. DOI: 10.14412/1995–4484–2016–667–673.Borisova M. A., Lukina G. V., Sigidin Y. A., Luchikhina E. L., Karateev D. E., Aronova E. S., Glukhova S. I. Comparative evaluation of the efficacy and safety of abatacept in patients with different duration of rheumatoid arthritis. Rheumatology Science and Practice. 2016; 54 (6): 667–673. (In Russ.) DOI: 10.14412/1995–4484–2016–667–673.Gülfe A, Wallman JK, Kristensen LE. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. Arthritis Research & Therapy. 2016; 18: 51. DOI: 10.1186/s13075–016–0950–0.Gülfe A, Wallman JK, Kristensen LE. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. Arthritis Research & Therapy. 2016; 18: 51. DOI: 10.1186/s13075–016–0950–0.Jørgensen TS, Turesson C, Kapetanovic M, et al. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry. Kuwana M, ed. PLoS ONE. 2017; 12 (2): e0169946. DOI: 10.1371/journal.pone.0169946.Jørgensen TS, Turesson C, Kapetanovic M, et al. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry. Kuwana M, ed. PLoS ONE. 2017; 12 (2): e0169946. DOI: 10.1371/journal.pone.0169946.Takeuchi T, Matsubara T, Ohta S, et al. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology (Oxford, England). 2015; 54 (4): 683–691. DOI: 10.1093/rheumatology/keu338.Takeuchi T, Matsubara T, Ohta S, et al. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology (Oxford, England). 2015; 54 (4): 683–691. DOI: 10.1093/rheumatology/keu338.Singh JA, Hossain A, Tanjong Ghogomu E et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016 May 13; (5): CD 012183. DOI: 10.1002/14651858.CD 012183.Singh JA, Hossain A, Tanjong Ghogomu E et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016 May 13; (5): CD 012183. DOI: 10.1002/14651858.CD 012183.Nüßlein HG, Alten R, Galeazzi M et al. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol. 2016 May-Jun; 34 (3): 489–99. Epub 2016 Mar 10.Nüßlein HG, Alten R, Galeazzi M et al. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol. 2016 May-Jun; 34 (3): 489–99. Epub 2016 Mar 10.Mariette X, Alten R, Nüßlein HG et al. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.Mariette X, Alten R, Nüßlein HG et al. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.Harigai M, Ishiguro N, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Modern Rheumatology. 2016; 26 (4): 491–498. DOI: 10.3109/14397595.2015.1123211.Harigai M, Ishiguro N, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Modern Rheumatology. 2016; 26 (4): 491–498. DOI: 10.3109/14397595.2015.1123211.Gottenberg JE, Courvoisier DS, Hernandez MV. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. Arthritis Rheumatol. 2016 Jun; 68 (6): 1346–52. DOI: 10.1002/art.39595.Gottenberg JE, Courvoisier DS, Hernandez MV. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. Arthritis Rheumatol. 2016 Jun; 68 (6): 1346–52. DOI: 10.1002/art.39595.Pieper J, Herrath J, Raghavan S CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients.Pieper J, Herrath J, Raghavan S CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients.Yamazaki H, Hirano F, Takeuchi T et al. Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan. Mod Rheumatol. 2017 Sep; 27 (5): 787–794. DOI: 10.1080/14397595.2016.1259715. Epub 2016 Dec 15.Yamazaki H, Hirano F, Takeuchi T et al. Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan. Mod Rheumatol. 2017 Sep; 27 (5): 787–794. DOI: 10.1080/14397595.2016.1259715. Epub 2016 Dec 15.

The authors declare that there are no conflicts of interest present.